A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer
Cancer Chemotherapy and Pharmacology, 08/17/2012
Bender BC et al. – This semimechanistic pharmacokinetic/pharmacodynamic (PK/PD) model accurately captures the cycle 1 platelet nadir, the downward drift noted in some patient platelet–time profiles, and the –8% incidence of grade ≥3Thrombocytopenia (TCP) with Trastuzumab emtansine (T–DM1) 3.6mg/kg q3w. This model supports T–DM1 3.6mg/kg q3w as a well–tolerated dose with minimal dose delays or reductions for TCP.